Liquidia Corporation

NASDAQ:LQDA

Biotechnology

Healthcare
$56.40 +0.34%

+$0.23 today

Market cap
$5.08B
Beta
0.59
P/E (TTM)
271.8
EPS (TTM)
$0.25
52W Low $11.85High $73.22

Volume 1.22M

Average 1.50M

LQDA Interest Income

Income earned on cash, deposits, and investments held by the company.

Liquidia CorporationNASDAQ: LQDA

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income growth accelerates

Q2 FY2026 interest income of $2.48M rose 56.3% year over year, ahead of the +4.5% change in trailing-twelve-month interest income. Sequentially, it rose 39.7% from the prior quarter. Over 3 fiscal years it compounded at +82.5% a year.

Context

  • Interest income amounted to 4.2% of revenue in FY2025, down 50.5 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +56.3% holds above the trailing-twelve-month pace of +4.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.48M+39.7% QoQ
Last fiscal yearDec 2025
$6.62M-13.5% YoY
LTMJun 2026
$7.56M+4.5% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.3%——
1 year-13.5%——
3-year CAGR+82.5%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
6.62M USD
Year-over-year change
-13.5%
4-year CAGR
+276.4%

Interest Income vs competitors

How LQDA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.5% is the 2nd highest of 4, against a peer median of -19.2%.
  • Interest income amounts to 1.7% of revenue for LQDA, versus a peer median of 5.2%.
LQDA Competitors
Interest Income for LQDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTHRUnited Therapeutics CorporationLTM Jun 2026$162.9M USD-19.2%+62.0%5.2%
INSMInsmed IncorporatedLTM Jun 2026$45.57M USD-25.8%+76.2%4.0%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 21.37M SEK+23.9%+196.9%1607.1%
LQDALiquidia CorporationLTM Jun 2026$7.56M USD+4.5%+82.5%1.7%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding LQDA) —-19.2%+76.2%5.2%

Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.85M15.94M17.49M14M158.32M
Cost of Revenue3.02M2.86M2.89M5.88M13.24M
Gross Profit9.83M13.08M14.6M8.12M145.08M
Gross Margin76.5%82.1%83.5%58.0%91.6%
Research & Development20.52M19.44M43.24M47.84M39.28M
Selling, General & Admin23.11M32.41M44.74M81.57M157.18M
Operating Expenses43.63M51.85M87.98M129.41M196.45M
Depreciation & Amortization5.61M3.65M2.18M2.2M1.53M
EBITDA(28.21M)(35.03M)(70.05M)(115.71M)(43.22M)
EBITDA Margin-219.4%-219.8%-400.6%-826.7%-27.3%
Operating Income(33.8M)(38.77M)(73.38M)(121.29M)(51.38M)
Operating Margin-263.0%-243.3%-419.6%-866.6%-32.5%
Interest Income33K1.09M3.47M7.65M6.62M
Interest Expense762K2.34M6.27M12.49M24.17M
Other Income / Expenses(782K)(2.25M)(5.12M)(9.1M)(17.55M)
Income Before Tax(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Pre-Tax Margin-269.0%-257.4%-448.9%-931.7%-43.5%
Income Tax Expense00000
Net Income(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Net Margin-269.0%-257.4%-448.9%-931.7%-43.5%
EPS (Basic)(0.70)(0.67)(1.21)(1.66)(0.80)
EPS (Diluted)(0.70)(0.67)(1.21)(1.66)(0.80)
Weighted Avg Shares49.68M60.96M64.99M78.71M86.06M
Weighted Avg Shares (Diluted)49.68M60.96M64.99M78.71M86.06M

Liquidia Corporation

NASDAQ:LQDA

Intrinsic Alpha fair value

Locked

Current Price

$56.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.